Overview: HIV-1 RNA CD3 CD4 Panel
Introduction: The HIV-1 RNA CD3 CD4 Panel is a diagnostic tool designed to monitor HIV-1 and immune status using whole blood samples. In India, ~2.4 million people live with HIV, with CD4 count and viral load essential for ART initiation (CD4 <350 or symptomatic) and monitoring suppression (<50 copies/mL). High morbidity from under-monitoring in rural/low-SES patients, limited labs, delayed ART switch leading to opportunistic infections or AIDS progression. Per immunology/microbiology practices aligned with NACO and WHO guidelines, the test combines PCR for HIV-1 RNA quantitative and flow cytometry for CD3/CD4 counts over 1-2 days with high accuracy, valuable for staging and treatment response. This diagnostic falls under viral load monitoring and targets HIV-positive patients on ART or pre-ART, addressing accurate detection to guide therapy adjustment. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise immune/virologic assessment and reducing AIDS mortality. Its whole blood-based approach ensures reliable integrated monitoring.
Other Names: HIV 1 RNA Pnl.
FDA Status: FDA approved, CLIA certified for microbiology/immunology/hematology, compliant with 2025 standards.
Historical Milestone: HIV RNA/CD4 standard; in India, scaled under NACO.
Purpose: The test assesses 6 parameters including HIV-1 RNA quantitative to guide monitoring, assess viral suppression/immune status, inform ART.
Test Parameters: 1. HIV-1 RNA Quantitative, 2. CD3 Count, 3. CD4 Count, 4. CD4 Percentage, 5. Total Lymphocytes, 6. Viral Load.
Pretest Condition: No fasting required; patients should have confirmed HIV.
Specimen: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell/RNA integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable for flow; RNA stable frozen.
Medical History: Patients should provide details on ART status, CD4 history, symptoms.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of poor monitoring including progression, benefits of assessment, and minimal discomfort from blood draw.
Procedural Considerations: The test involves sample processing using PCR and flow cytometry by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low CD4 can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: High viral load/low CD4 indicates poor control, necessitating specialist input.
Specialist Consultation: HIV specialists should be consulted for management.
Additional Supporting Tests: Resistance testing for confirmation.
Test Limitations: Requires fresh sample for flow; comprehensive approach required.
References: Indian Journal of Medical Microbiology 2024, HIV Studies India 2023.
